ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,638.94
2.13%
US Tech 100
19,167.20
2.31%
다우존스 지수
41,488.19
1.65%
Bitcoin
84,233.26
-0.14%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Kiniksa Pharmaceuticals International PLC (KNSA) 시세

Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals International PLC (KNSA)

NASDAQ
22.61
0.45
(2.03%)
마감 16 3월 5:00AM
15분 지연
18.1737
-4.44
(-19.62%)
시간외 거래: 8:51AM
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
18.1737
매수가
17.88
매도가
28.30
거래량
595,103
22.0201 일간 변동폭 22.86
16.56 52주 범위 28.15
market_cap
1.32B
전일 종가
22.16
개장가
22.36
최근 거래 시간
100
@
18.1737
(formt)
마지막 거래 시간
재정 규모
US$ 13,461,704
VWAP
22.6208
평균 볼륨(3m)
613,226
발행 주식
72,644,240
배당수익률
-
주가수익률
-37.99
주당순이익(EPS)
-0.59
매출
423.24M
순이익
-43.19M

Kiniksa Pharmaceuticals International PLC 정보

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurre... Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.kiniksa.com
본부
London, Gbr
설립됨
-
Kiniksa Pharmaceuticals International PLC is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker KNSA. The last closing price for Kiniksa Pharmaceuticals was US$22.16. Over the last year, Kiniksa Pharmaceuticals shares have traded in a share price range of US$ 16.56 to US$ 28.15.

Kiniksa Pharmaceuticals currently has 72,644,240 shares in issue. The market capitalisation of Kiniksa Pharmaceuticals is US$1.61 billion. Kiniksa Pharmaceuticals has a price to earnings ratio (PE ratio) of -37.99.

KNSA 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
15 3월 2025
KNSA (2.03%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
13 3월 2025
KNSA (2.03%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
11 3월 2025
KNSA (2.03%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
26 2월 2025
KNSA (2.03%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
26 2월 2025
KNSA (2.03%)

Form 8-K - Current report
Edgar (US Regulatory)
25 2월 2025
KNSA (2.03%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-3.0063-14.194050991521.1822.9418.173763774821.67202283CS
4-1.7463-8.7665662650619.9222.9418.173769995420.79273778CS
12-2.1563-10.606492867720.3322.9417.8261322620.11471225CS
26-7.2063-28.393617021325.3828.1517.8246872321.63440458CS
52-2.1363-10.518463810920.3128.1516.5643281421.57477534CS
1568.583789.50677789369.5928.157.3640386317.05470092CS
2600.07370.40718232044218.1337.3640217216.79459194CS

KNSA - Frequently Asked Questions (FAQ)

What is the current Kiniksa Pharmaceuticals share price?
The current share price of Kiniksa Pharmaceuticals is US$ 18.1737
How many Kiniksa Pharmaceuticals shares are in issue?
Kiniksa Pharmaceuticals has 72,644,240 shares in issue
What is the market cap of Kiniksa Pharmaceuticals?
The market capitalisation of Kiniksa Pharmaceuticals is USD 1.61B
What is the 1 year trading range for Kiniksa Pharmaceuticals share price?
Kiniksa Pharmaceuticals has traded in the range of US$ 16.56 to US$ 28.15 during the past year
What is the PE ratio of Kiniksa Pharmaceuticals?
The price to earnings ratio of Kiniksa Pharmaceuticals is -37.99
What is the cash to sales ratio of Kiniksa Pharmaceuticals?
The cash to sales ratio of Kiniksa Pharmaceuticals is 3.88
What is the reporting currency for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Kiniksa Pharmaceuticals?
The latest annual turnover of Kiniksa Pharmaceuticals is USD 423.24M
What is the latest annual profit for Kiniksa Pharmaceuticals?
The latest annual profit of Kiniksa Pharmaceuticals is USD -43.19M
What is the registered address of Kiniksa Pharmaceuticals?
The registered address for Kiniksa Pharmaceuticals is THIRD FLOOR, 23 OLD BOND STREET, LONDON, W1S 4PZ
What is the Kiniksa Pharmaceuticals website address?
The website address for Kiniksa Pharmaceuticals is www.kiniksa.com
Which industry sector does Kiniksa Pharmaceuticals operate in?
Kiniksa Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
RDUSRadius Recycling Inc
US$ 27.902
(104.26%)
8.53M
BONBon Natural Life Ltd
US$ 1.40
(90.29%)
84M
SUNESUNation Energy Inc
US$ 0.5213
(62.96%)
513.96M
WHLRLWheeler Real Estate Investment Trust Inc
US$ 255.00
(39.80%)
222
AAOIApplied Optoelectronics Inc
US$ 22.105
(39.29%)
17.01M
GLSTUGlobal Star Acquisition Inc
US$ 2.00
(-69.23%)
421
CURRCurrenc Group Inc
US$ 2.03
(-41.33%)
1.42M
ADTXAditxt Inc
US$ 0.0201
(-39.82%)
240.2M
HEPAHepion Pharmaceuticals Inc
US$ 0.0228
(-39.68%)
161.52M
WKSPWorksport Ltd
US$ 0.36205
(-35.45%)
4.96M
SUNESUNation Energy Inc
US$ 0.5213
(62.96%)
513.96M
NVDANVIDIA Corporation
US$ 121.67
(5.27%)
277.56M
ADTXAditxt Inc
US$ 0.0201
(-39.82%)
240.2M
HEPAHepion Pharmaceuticals Inc
US$ 0.0228
(-39.68%)
161.52M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 9.225
(7.64%)
160.21M

KNSA Discussion

게시물 보기
Monksdream Monksdream 6 월 전
KNSA inching back up
👍️0
DonDonDonDon DonDonDonDon 4 년 전
No bueno. I guess HGEN's lenzilumab is the best of the anti-GM-CSF drugs for Covid. Lenzilumab's trial showed 54% efficacy. It is guaranteed an EUA within a couple of weeks yet its stock is 20% below where it was a month ago. It dropped 2 days ago because they diluted 5 million shares to pay for manufacturing.

https://www.rheumatologyadvisor.com/home/general-rheumatology/mavrilimumab-outcomes-patients-with-severe-covid19-pneumonia-hyperinflammation/
👍️0
DonDonDonDon DonDonDonDon 4 년 전
It was recently discovered that the protein GM-CSF is the cytokine responsible for severe Covid and death. Kiniksa will surely get a government grant to do an additional trial. Here is a BBC article about the trial that determined that GM-CSF is key to Covid:

https://www.bbc.com/news/health-56352128

Here is an additional article stating that KNSA and HGEN are the two companies with the best GM-CSF drugs to combat Covid:

https://www.clinicaltrialsarena.com/comment/humanigens-and-kiniksas-anti-gm-csf-antibodies-likely-to-garner-a-place-for-nonventilated-covid-19-patients/
👍️0
Femto99 Femto99 4 년 전
PT= $30-40 (by or around March 31st)
https://msmoneymoves.com/2021/02/17/knsa-report/
👍️0
Femto99 Femto99 4 년 전
PDUFA Mar21
👍️0

최근 히스토리

NASDAQ
KNSA
Kiniksa Pharmaceuticals
NYSE
ATAQ.U
Altimar Acquisition Corp...
NASDAQ
CBTMX
Ci Canadian Bond Fund Cl...
NASDAQ
CFUTX
Ci Portfolio Series Inco...
NASDAQ
ZAEUZX
Ascendent Capital Partne...
TSXV
AFF
Affinity Metals
NASDAQ
CDQOX
Ci Global Equity Corpora...
BOV
GUAR3Q
GUARARAPES ON
EU
SPYP
Leverage Shares 1x Short...
NASDAQ
ZAATMX
Abry Partners V
NASDAQ
ZADYYX
Arbor Debt Opportunities...
BITMOT
865374
Romania Tf 2,75% Fb26 Eur
NASDAQI
FDIV
First Trust Strategic In...
TSXV
RTC
NASDAQ
FCKAX
Beutel Goodman Fundament...
NASDAQ
FBEBX
Agf Elements Conservativ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지